Primary Catalyst Driving Glioblastoma Multiforme (GBM) Treatment Market Evolution in 2025: Rising Cases Of Brain Disorder Driver

What combination of drivers is leading to accelerated growth in the glioblastoma multiforme (gbm) treatment market?
The escalating incidence of neurologic anomalies is anticipated to propel the expansion of the glioblastoma multiforme (GBM) treatment market. Neurologic anomalies refer to the abnormal functionality of the brain, nerves spread throughout the body, and spinal cord. The surge in these disorders, particularly glioblastoma multiforme (GBM), stems from various factors such as an aging population, weakened immune systems, frequent overdiagnosis, ionizing radiation, air pollution, amongst others. These factors underscore the need for treatment provisions to enhance general health. For example, a 2022 report from the American Cancer Society, a US voluntary health organization committed to cancer eradication, recorded approximately 25,050 malignant brain or spinal cord tumor cases. Hence, the proliferating rate of neurologic disorders is fueling the expansion of the glioblastoma multiforme (GBM) treatment market.

Get Your Glioblastoma Multiforme (GBM) Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

What is the projected compound annual growth rate (CAGR) of the glioblastoma multiforme (gbm) treatment market from 2025 to 2034, and what factors influence it?
The market for treating glioblastoma multiforme (GBM) has been expanding quickly over the past few years. The market, which is set to increase from $2.48 billion in 2024 to $2.74 billion in 2025, will see a compound annual growth rate (CAGR) of 10.2%. This historical growth has been driven by the increasing number of cases, improvements in diagnostic methods, funding for clinical trials and research, alliances and partnerships, and a deeper knowledge of tumour biology.

Anticipations are high for a swift expansion in the glioblastoma multiforme (GBM) treatment market in the upcoming years. By 2029, it is predicted to achieve a worth of $4.1 billion, soaring at a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this anticipated growth within the forecast duration include breakthroughs in immunotherapies, advancements in precision medicine, enhanced understanding of genetic markers, patient support and awareness, along with government assistance for rare diseases. Foreseen trends during this period encompass exploration into combination therapies, incorporation of artificial intelligence in diagnosis and treatment methods, increased uptake of immunotherapeutic strategies, and advancement in medical tools and equipment.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp

How are the latest trends influencing the growth of the glioblastoma multiforme (gbm) treatment market?
Innovation in wearable and portable devices is the primary focus of leading companies in the market to maintain their market position. These innovations aim to provide enhanced functionality, accessibility, and comfort to the users, thereby addressing the increasing demand for easy and effective healthcare solutions. Novocure, a notable oncology company from Jersey, introduced an innovative wearable and portable treatment system, the Optune Gio, for newly diagnosed glioblastoma (GBM) patients in 2023. Having received FDA approval, this device uses Tumor Treating Fields (TTFields) - alternating electric fields known to hinder cancer cell division, which could potentially prolong patients' lives. Designed with user comfort in mind, the Optune Gio weighs only 2.7 pounds and is made to be worn during everyday activities.

What are the major segments of the glioblastoma multiforme (gbm) treatment market and their role in driving growth?
The glioblastoma multiforme (GBM) treatment market covered in this report is segmented -

1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Surgery: Tumor Resection, Biopsy Procedures
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens
4) By Targeted Therapy: EGFR Inhibitors, Other Targeted Agents
5) By Tumor Treating Field (TTF) Therapy: Device-Based TTF Treatment
6) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8803

Which regions are key players in the growth of the glioblastoma multiforme (gbm) treatment market?
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the glioblastoma multiforme (gbm) treatment market?
Major companies operating in the glioblastoma multiforme (GBM) treatment market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=8803&type=smp

What Is Covered In The Glioblastoma Multiforme (GBM) Treatment Global Market Report?

•Market Size Forecast: Examine the glioblastoma multiforme (gbm) treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the glioblastoma multiforme (gbm) treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the glioblastoma multiforme (gbm) treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the glioblastoma multiforme (gbm) treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the glioblastoma multiforme (gbm) treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the glioblastoma multiforme (gbm) treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the glioblastoma multiforme (gbm) treatment market.
•Competitive Landscape: Review strategic developments in the glioblastoma multiforme (gbm) treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.